The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.
Consumer companies are increasingly betting on the male grooming and personal care categories. Wasted digital ad spend in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback